Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas S Goodin

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
BMC Neurology|October 30, 2010
The genetic basis of multiple sclerosis: a model for MS susceptibilityDouglas S Goodin
Psychosomatic Medicine|March 25, 2004
Relationship between multiple sclerosis exacerbations and stressDouglas S Goodin
Annals of Neurology|March 28, 2006
Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?Douglas S Goodin
Journal of Neurology, Neurosurgery, and Psychiatry|July 3, 2024
Pathogenesis of multiple sclerosis: genetic, environmental and random mechanismsDouglas S Goodin
Journal of Neurology|November 19, 2004
Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-responseDouglas S Goodin
Neurology|September 27, 2006
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating eventDouglas S Goodin
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2011
Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous roadDouglas S Goodin
Neurology|October 13, 2006
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisDouglas S Goodin
Plos One|December 29, 2012
The genetic and environmental bases of complex human-disease: extending the utility of twin-studiesDouglas S Goodin
Seminars in Neurology|May 28, 2013
The use of interferon Beta and glatiramer acetate in multiple sclerosisDouglas S Goodin
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
BMC Neurology|October 30, 2010
The genetic basis of multiple sclerosis: a model for MS susceptibilityDouglas S Goodin
Psychosomatic Medicine|March 25, 2004
Relationship between multiple sclerosis exacerbations and stressDouglas S Goodin
Annals of Neurology|March 28, 2006
Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?Douglas S Goodin
Journal of Neurology, Neurosurgery, and Psychiatry|July 3, 2024
Pathogenesis of multiple sclerosis: genetic, environmental and random mechanismsDouglas S Goodin
Journal of Neurology|November 19, 2004
Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-responseDouglas S Goodin
Neurology|September 27, 2006
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating eventDouglas S Goodin
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2011
Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous roadDouglas S Goodin
Neurology|October 13, 2006
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisDouglas S Goodin
Plos One|December 29, 2012
The genetic and environmental bases of complex human-disease: extending the utility of twin-studiesDouglas S Goodin
Seminars in Neurology|May 28, 2013
The use of interferon Beta and glatiramer acetate in multiple sclerosisDouglas S Goodin
Pageof 8